Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis

International Journal of Neuroscience

Volumn 121, Issue 9, 2011, Pages 510-520

  Hasseldam, Henrik ^a   Fryd Johansen, Flemming ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Axonal degeneration; Cannabinoids; Demyelination; Experimental autoimmune encephalomyelitis; Inflammation; Multiple sclerosis

Indexed keywords

[2,3 DIHYDRO 5 METHYL 3 (4 MORPHOLINYLMETHYL)PYRROLO[1,2,3 DE] 1,4 BENZOXAZIN 6 YL] 1 NAPHTHALENYLMETHANONE; CALPAIN; CANNABINOID DERIVATIVE; CASPASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; NEUROPROTECTIVE AGENT; RANTES; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WIN 55 212 2;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN NERVE CELL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NONHUMAN; OLIGODENDROGLIA; QUANTITATIVE ANALYSIS; RAT; REGULATORY T LYMPHOCYTE; RELAPSE;

AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BENZOXAZINES; CANNABINOIDS; CASPASE 3; CASPASE 9; CELL COUNT; CENTRAL NERVOUS SYSTEM; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MACROPHAGES; MORPHOLINES; NAPHTHALENES; NERVE DEGENERATION; NEUROLOGIC EXAMINATION; NEURONS; OLIGODENDROGLIA; POLY(ADP-RIBOSE) POLYMERASES; RATS; SPINAL CORD; T-LYMPHOCYTES; TIME FACTORS;

EID: 80051511846     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.582237     Document Type: Article

References (44)

1. Ahmed, Z., Doward, A. I., Pryce, G., Taylor, D. L., Pocock, J. M., Leonard, J. P., et al. (2002). A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis: Infamma-tion versus degeneration. American Journal of Pathology, 161(5), 1577-1586. (Pubitemid 35265518)
2. Arevalo-Martin, A., Vela, J. M., Molina-Holgado, E., Borrell, J., & Guaza, C. (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis. Journal of Neuroscience, 23(7), 2511-2516. (Pubitemid 36418583)
3. Baker, D., Jackson, S. J., & Pryce, G. (2007). Cannabinoid control of neuroinfammation related to multiple sclerosis. British Journal of Pharmacology, 152(5), 649-654. (Pubitemid 350034985)
4. Benkhoucha, M., Santiago-Raber, M. L., Schneiter, G., Choffon, M., Funakoshi, H., Nakamura, T.,et al. (2010). Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 107(14), 6424-6429.
5. Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T., & Bruck, W. (2000). Acute axonal injury in multiple sclerosis. Correlation with demyelination and infammation. Brain, 123 (Pt 6), 1174-1183. (Pubitemid 30312109)
6. Croxford, J. L., & Miller, S. D. (2003). Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabi-noid R+WIN55,212. Journal of Clinical Investigation, 111(8), 1231-1240. (Pubitemid 36519940)
7. Croxford, J. L., Pryce, G., Jackson, S. J., Ledent, C., Giovannoni, G., Pertwee, R. G., et al. (2008). Cannabinoid-mediated neu-roprotection, not immunosuppression, may be more relevant to multiple sclerosis. Journal of Neuroimmunology, 193(1-2), 120-129.
8. Das, A., Guyton, M. K., Butler, J. T., Ray, S. K., & Banik, N. L. (2008). Activation of calpain and caspase pathways in demyeli-nation and neurodegeneration in animal model of multiple sclerosis. CNS & Neurological Disorders Drug Targets, 7(3), 313-320.
9. Das, A., Guyton, M. K., Matzelle, D. D., Ray, S. K., & Banik, N. L. (2008). Time-dependent increases in protease activities for neu-ronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 86(13), 2992-3001.
10. Dong, M., Liu, R., Guo, L., Li, C., & Tan, G. (2008). Pathological fndings in rats with experimental allergic encephalomyeli-tis. Acta Pathologica, Microbiologica et Immunologica Scandinavica, 116(11), 972-984.
11. Duriez, P. J., & Shah, G. M. (1997). Cleavage of poly(ADP-ribose) polymerase: A sensitive parameter to study cell death. Biochemistry & Cell Biology, 75(4), 337-349. (Pubitemid 127733184)
12. Furtado, G. C., Olivares-Villagomez, D., Curotto de Lafaille, M. A., Wensky, A. K., Latkowski, J. A., & Lafaille, J. J. (2001). Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunological Reviews, 182, 122-134. (Pubitemid 33070213)
13. Gonsette, R. E. (2008). Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. Journal of Neurological Sciences, 274(1-2), 48-53.
14. Guyton, M. K., Wingrave, J. M., Yallapragada, A. V., Wilford, G. G., Sribnick, E. A., Matzelle, D. D., et al. (2005). Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. Journal of Neuro-science Research, 81(1), 53-61. (Pubitemid 41139110)
15. Guzman, M., Sanchez, C., & Galve-Roperh, I. (2002). Cannabinoids and cell fate. Pharmacology & Therapeutics, 95(2), 175-184. (Pubitemid 35232135)
16. Hasseldam, H., & Johansen, F. F. (2010). Neuroprotection without immunomodulation is not suffcient to reduce frst relapse severity in experimental autoimmune encephalomyelitis. Neu-roimmunomodulation, 17(4), 252-264.
17. Hassen, G. W., Feliberti, J., Kesner, L., Stracher, A., & Mokhtarian, F. (2008). Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyeli-tis. Brain Research, 1236, 206-215
18. Hegde, V. L., Hegde, S., Cravatt, B. F., Hofseth, L. J., Nagarkatti, M., & Nagarkatti, P. S. (2008). Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: Involvement of regulatory T cells. Molecular Pharmacology, 74(1), 20-33. (Pubitemid 351872155)
19. Jackson, S. J., Lee, J., Nikodemova, M., Fabry, Z., & Duncan, I. D. (2009). Quantifcation of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Journal of Neuropathology & Experimental Neurology, 68(6), 616-625.
20. Jackson, S. J., Pryce, G., Diemel, L. T., Cuzner, M. L., & Baker, D. (2005). Cannabinoid-receptor 1 null mice are susceptible to neu-roflament damage and caspase 3 activation. Neuroscience, 134(1), 261-268. (Pubitemid 40943652)
21. Katona, S., Kaminski, E., Sanders, H., & Zajicek, J. (2005). Cannabi-noid infuence on cytokine profle in multiple sclerosis. Clinical & Experimental Immunology, 140(3), 580-585. (Pubitemid 40813971)
22. Killestein, J., Hoogervorst, E. L., Reif, M., Blauw, B., Smits, M., Uit-dehaag, B. M., et al. (2003). Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. Journal of Neu-roimmunology, 137(1-2), 140-143. (Pubitemid 36351576)
23. Kohm, A. P., Carpentier, P. A., Anger, H. A., & Miller, S. D. (2002). Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specifc autoreactive immune responses and central nervous system infammation during active experimental autoimmune encephalomyelitis. Journal of Immunology, 169(9), 4712-4716. (Pubitemid 35217131)
24. Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S.,et al. (2006). IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. Journal of Immunology, 177(1), 566-573. (Pubitemid 43939170)
25. Korn, T. (2008). Pathophysiology of multiple sclerosis. Journal of Neurological, 255(Suppl 6), 2-6.
26. Linker, R. A., Brechlin, P., Jesse, S., Steinacker, P., Lee, D. H., Asif, A. R. et al. (2009). Proteome profling in murine models of multiple sclerosis: Identifcation of stage specifc markers and culprits for tissue damage. PLoS ONE, 4(10), e7624.
27. Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., & Behl, C. (2002). Neuroprotective properties of cannabinoids against ox-idative stress: Role of the cannabinoid receptor CB1. Journal of Neurochemistry, 80(3), 448-456. (Pubitemid 36383028)
28. McPartland, J. M., Glass, M., & Pertwee, R. G. (2007). Meta-analysis of cannabinoid ligand binding affnity and receptor distribution: Interspecies differences. British Journal of Pharmacology, 152(5), 583-593. (Pubitemid 350034970)
29. Nicot, A., Ratnakar, P. V., Ron, Y., Chen, C. C., & Elkabes, S. (2003). Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain, 126(Pt 2), 398-412. (Pubitemid 36172744)
30. Paintlia, A. S., Paintlia, M. K., Singh, I., & Singh, A. K. (2008). Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Experimental Neurology, 214(2), 168-180.
31. Petitet, F., Jeantaud, B., Bertrand, P., & Imperato, A. (1999). Cannabinoid penetration into mouse brain as determined by ex vivo binding. European Journal of Pharmacology, 374(3), 417-421. (Pubitemid 29313454)
32. Pfaff, M. W. (2001). A new mathematical model for relative quantif-cation in real-time RT-PCR. Nucleic Acids Research, 29(9), e45.
33. Piani, D., Frei, K., Do, K. Q., Cuenod, M., & Fontana, A. (1991). Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neuroscience Letters, 133(2), 159-162.
34. Pitt, D., Werner, P., & Raine, C. S. (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nature Medicine, 6(1), 67-70. (Pubitemid 30048528)
35. Qi, X., Lewin, A. S., Sun, L., Hauswirth, W. W., & Guy, J. (2007). Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Investigative Ophthalmology & Visual Science, 48(2), 681-691. (Pubitemid 351260701)
36. Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65(6), 812-819. (Pubitemid 41362120)
37. Sadri, S., Bahrami, F., Khazaei, M., Hashemi, M., & Asgari, A. (2010). Cannabinoid receptor agonist WIN-55,212-2 protects differentiated PC12 cells from organophosphorus-induced apoptosis. International Journal of Toxicology, 29(2), 201-208.
38. Sarne, Y., & Keren, O. (2004). Are cannabinoid drugs neurotoxic or neuroprotective? Medical Hypotheses, 63(2), 187-192. (Pubitemid 38968713)
39. Trapp, B. D., & Nave, K. A. (2008). Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience, 31, 247-269.
40. Wujek, J. R., Bjartmar, C., Richer, E., Ransohoff, R. M., Yu, M., Tuohy, V. K., et al. (2002). Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. Journal of Neuropathology & Experimental Neurology, 61(1), 23-32. (Pubitemid 34027718)
41. Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., et al. (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multi-centre randomised placebo-controlled trial. Lancet, 362(9395), 1517-1526. (Pubitemid 37410189)
42. Zhang, X., Koldzic, D. N., Izikson, L., Reddy, J., Nazareno, R. F., Sakaguchi, S., et al. (2004). IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. International Immunology, 16(2), 249-256. (Pubitemid 38195655)
43. Zheng, S. G., Wang, J., & Horwitz, D. A. (2008). Cutting edge: Foxp3+CD4+CD25 +regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. Journal of Immunology, 180(11), 7112-7116.
44. Zhuang, S. Y., Bridges, D., Grigorenko, E., McCloud, S., Boon, A., Hampson, R. E., et al. (2005). Cannabinoids produce neuropro-tection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology, 48(8), 1086-1096. (Pubitemid 40725981)